Holen Sie sich die Stockscreener-App
4.33
5.46%
-0.25
Schlusskurs vom Vortag:
$4.58
Offen:
$4.57
24-Stunden-Volumen:
17.77M
Relative Volume:
0.42
Marktkapitalisierung:
$2.25B
Einnahmen:
$64.60M
Nettoeinkommen (Verlust:
$-377.75M
KGV:
-2.7935
EPS:
-1.55
Netto-Cashflow:
$-335.64M
1W Leistung:
-8.07%
1M Leistung:
-6.88%
6M Leistung:
-16.25%
1J Leistung:
-37.97%
1-Tages-Spanne:
$4.31
$4.6399
1-Wochen-Bereich:
$4.31
$5.0899
52-Wochen-Spanne:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Vergleichen Sie RXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.33 | 2.38B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025) - ts2.tech
Recursion rises on new data for asset for polyps - MSN
Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment (RXRX) - Seeking Alpha
Is Early REC-4881 Trial Success Reframing the AI-Drug Discovery Investment Case For Recursion (RXRX)? - simplywall.st
Cautious Optimism for Recursion Pharmaceuticals: Promising TUPELO Study Results Lead to Hold Rating - TipRanks
Norges Bank Buys Shares of 3,169,938 Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Is There an Opportunity in Recursion Pharmaceuticals After Recent AI Drug Discovery Rally? - Yahoo Finance
Recursion Pharmaceuticals Reports Positive TUPELO Trial Results - TipRanks
Recursion Pharmaceuticals reports positive TUPELO trial results - MSN
Recursion Pharmaceuticals (RXRX): Revisiting Valuation After a Tentative Share Price Rebound - simplywall.st
Why Recursion Pharamaceuticals Topped the Market Today - MSN
Why Recursion Pharamaceuticals Topped the Market Today - The Motley Fool
Recursion Pharmaceuticals: Unraveling the Surge - timothysykes.com
Recursion Pharmaceuticals (RXRX) up 6.5% since last earnings report: Can it continue? - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap UpTime to Buy? - MarketBeat
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and TUPELO Trial Data - Quiver Quantitative
Promising Clinical Study Results and FDA Meeting Propel Buy Rating for Recursion Pharmaceuticals - TipRanks
Why Are Shares Of Recursion Pharmaceuticals Higher Today? - Benzinga
Recursion Pharmaceuticals Jumps as FAP Drug Candidate Shows Durable Efficacy - TradingPedia
Why Recursion Pharmaceuticals Shares Are in Focus Today - TipRanks
Recursion's Tupelo trial phase 1b/2 results show polyp burden reductions in FAP at 25 weeks - marketscreener.com
Recursion Pharmaceuticals stock surges after positive FAP trial data By Investing.com - Investing.com UK
Recursion’s FAP drug shows durable polyp reduction in phase 1b/2 trial - Investing.com
RXRX: REC-4881 achieved rapid, durable polyp burden reduction in FAP with a favorable safety profile - TradingView
Recursion Pharmaceuticals Announces Positive Phase 1b/2 Results for REC-4881 in FAP - TradingView
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO - GlobeNewswire
Recursion Pharmaceuticals (RXRX) Is Up 8.0% After TUPELO REC-4881 Trial Data ReleaseWhat's Changed - Yahoo Finance
Jim Cramer on Recursion: "It Is so Low That It Comes in Under the Category of Speculative" - Finviz
Jim Cramer on Recursion: “It Is so Low That It Comes in Under the Category of Speculative” - Insider Monkey
Growth Value: Can Recursion Pharmaceuticals Inc stock maintain growth trajectoryQuarterly Portfolio Report & AI Enhanced Trading Alerts - moha.gov.vn
Recursion pharma CEO Gibson sells $185,200 in shares - Investing.com
Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 220,000 Shares of Stock - MarketBeat
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? - sharewise.com
Jim Cramer: This Health Care Stock Has Been 'Horrendous' - Benzinga
Recursion Pharmaceuticals Registers Resale of 7 Million Shares - MSN
Recursion Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Recursion Pharmaceuticals: Is It the Right Time to Buy? - StocksToTrade
Cramer's Lightning Round: Recursion Pharmaceuticals 'has been horrendous' - CNBC
Recursion Pharmaceuticals Insider Sold Shares Worth $961,400, According to a Recent SEC Filing - marketscreener.com
Recursion Pharmaceuticals: Is This Just The Beginning? - timothysykes.com
A Look At The Fair Value Of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - 富途牛牛
RECURSION PHARMACEUTICALS INC (RXRX.MX) Q1 FY2025 earnings call transcript - Yahoo Finance
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Clinical Data Readout - Quiver Quantitative
Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade - InvestorPlace
Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com
Capital Fund Management S.A. Has $3.65 Million Stock Holdings in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Can Recursion Pharmaceuticals Inc. stock continue upward trendQuarterly Profit Report & Advanced Swing Trade Entry Alerts - Newser
Is Recursion Pharmaceuticals Inc. stock attractive for hedge fundsMarket Trend Review & Verified Technical Signals - Newser
Quadrature Capital Ltd Takes Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion to Host Webinar on Tupelo Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis on Dec. 8 - TradingView
Recursion to present updated FAP trial data of REC-4881 in webinar - Investing.com Australia
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Recursion Pharmaceuticals Inc-Aktie (RXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Borgeson Blake | Director |
Dec 02 '25 |
Sale |
4.37 |
220,000 |
961,400 |
6,869,863 |
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):